First Phosphate and BioVie Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

RedChip will air interviews with First Phosphate (PHOS) and BioVie (BIVI) this weekend to discuss near-term catalysts. First Phosphate highlighted ~$21.5M in non-repayable Canadian government funding secured in six months to support mine concentrator development and related infrastructure toward feasibility/permitting and a final investment decision for its Bégin-Lamarche phosphate/LFP supply chain. BioVie described Phase 2 bezisterim in Parkinson’s disease results with statistically significant improvements vs. placebo and outlined next steps including FDA End-of-Phase 2 prep, a potential pivotal Phase 3 trial, plus topline long-COVID data expected after Labor Day following a $13M grant.

Analysis

This is mostly a distribution event, not a fundamental one. For PHOS, the meaningful read-through is not the TV slot itself but that non-dilutive funding reduces near-term financing risk and buys time to prove whether the resource can graduate from story stock to bankable project. The market can briefly re-rate microcaps on broader media reach, but without a financing plan, offtake, or feasibility de-risking, any move is likely to be liquidity-driven and fade over 1-3 sessions.

BIVI is the higher-quality catalyst because there is an actual data event ahead. A clean long-COVID readout could reopen partnering and soften dilution risk for 6-12 months; a miss would likely reprice the name back to a capital-raise story regardless of the Parkinson’s signal. The key is that small-cap neuro/long-COVID biotech trades on evidence quality, not headline visibility, so the stock’s path is likely binary into the next readout.

The contrarian point is that the market may be overvaluing national TV exposure as a proxy for institutional validation. For PHOS, the real risk is capital intensity and Chinese cost competition in LFP materials; for BIVI, the real risk is that the current optimism gets ahead of regulatory feedback and reproducibility. Falsifiers are straightforward: PHOS needs a credible path to FID/offtake/permitting, while BIVI needs statistically clean efficacy plus FDA guidance that preserves a registrational path.

Key Decisions for Investors

• PHOS: do not chase the broadcast pop; if borrow is available, fade any 1-3 day spike and cover on the first substantive filing (offtake, feasibility, or financing). Risk/reward is skewed to a fast retracement if there is no new capital de-risking.
• BIVI: build only a small starter long ahead of the long-COVID readout, sized for binary downside, and consider trimming into any pre-data run-up. The upside is a partnering/FDA reset; the downside is immediate dilution pressure if the dataset is messy.
• Pair trade: long BIVI / short PHOS as a catalyst-quality spread. BIVI has a dated clinical readout within weeks; PHOS is still a long-duration, funding-dependent narrative. Use PHOS short only if borrow cost is manageable and cover on any real project milestone.
• Watch item, not trade: if PHOS announces additional non-dilutive funding or a binding offtake agreement within 1-2 quarters, reassess for a structural re-rate. Absent that, treat media exposure as a retail-liquidity event.
• For BIVI, set a hard thesis checkpoint at the long-COVID topline data and FDA feedback. If either is weak, exit the view quickly; the stock likely trades back to financing risk rather than pipeline optionality.